CRL vs PBYI: fair value comparison
Charles River Laboratories International, Inc. and Puma Biotechnology, Inc. · Updated 2026-10-19
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PBYI currently sits closer to the top of our ranking by discount to fair value. PBYI carries the stronger quality grade.
| CRL | PBYI | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $301.79 | $9.83 |
| 12-month range | $149.93–$310.77 | $4.73–$10.52 |
| Rank by discount to fair value | #108 of 108 Healthcare | #95 of 108 Healthcare |
| Quality grade | F | A |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Uptrend |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: CRL fair value analysis · PBYI fair value analysis